124
Views
0
CrossRef citations to date
0
Altmetric
COMMENTARIES

Commentary on ‘‘Should the diagnostic boundaries of schizophrenia be expanded?’’

, , &
Pages 107-112 | Published online: 03 Mar 2011
 

Acknowledgements

The authors were supported by a National Health and Medical Research Council (NHMRC) Program Grant (ID: 566529). ARY was supported by a NHMRC Senior Research Fellowship (ID: 566593). CP was supported by a NHMRC Senior Principal Research Fellowship (ID: 628386).

In the last 5 years, ARY has received Honoraria from Eli Lilly, Bristol Myer Squibb, and Janssen-Cilag. PDM has received Honoraria from Eli Lilly, Janssen-Cilag, Pfizer, and Astra Zeneca. ARY and PDM are investigators on an Investigator Initiated study of the at risk group funded by Astra Zeneca. CP has received grant support from Janssen-Cilag, Eli Lilly, Hospira (Mayne), and Astra Zeneca, and has provided consultancy to Janssen-Cilag, Eli Lilly, Hospira (Mayne), Astra Zeneca, Pfizer, Schering Plough, and is an investigator on an Investigator Initiated study of bipolar disorder funded by Astra Zeneca. SJW has no disclosures.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.